Skip to main content
Clinical Trials/IRCT20170117032025N9
IRCT20170117032025N9
Not yet recruiting
Phase 2

Study of the therapeutic effect of the combination of altplas and ibtifibatide (integrilin) in comparison with altplas (r-TPA) alone, in the treatment of acute ischemic stroke

Hamedan University of Medical Sciences0 sites50 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Acute Ischemic Stroke.
Sponsor
Hamedan University of Medical Sciences
Enrollment
50
Status
Not yet recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients should have a serious measurable neurological defect on the NIHSS stroke scale due to focal ischemia of the brain (NIHSS score\> 5\).
  • Intravenous therapy should be started within 3 hours of the onset of stroke symptoms.

Exclusion Criteria

  • Suspect subarachnoid hemorrhage, even if the brain CT scan is normal

Outcomes

Primary Outcomes

Not specified

Similar Trials